ATE411038T1 - S100 protein als aktivator neutrophiler zellen zur verminderung der neutropenie bei der krebsbehandlung - Google Patents

S100 protein als aktivator neutrophiler zellen zur verminderung der neutropenie bei der krebsbehandlung

Info

Publication number
ATE411038T1
ATE411038T1 AT04723142T AT04723142T ATE411038T1 AT E411038 T1 ATE411038 T1 AT E411038T1 AT 04723142 T AT04723142 T AT 04723142T AT 04723142 T AT04723142 T AT 04723142T AT E411038 T1 ATE411038 T1 AT E411038T1
Authority
AT
Austria
Prior art keywords
protein
activator
cancer treatment
neutrophil cells
reduce neutropenia
Prior art date
Application number
AT04723142T
Other languages
English (en)
Inventor
Philippe Tessier
Karen Vandal
Pascal Rouleau
Carle Ryckman
Original Assignee
Univ Laval
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Laval filed Critical Univ Laval
Application granted granted Critical
Publication of ATE411038T1 publication Critical patent/ATE411038T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT04723142T 2003-03-28 2004-03-25 S100 protein als aktivator neutrophiler zellen zur verminderung der neutropenie bei der krebsbehandlung ATE411038T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45802203P 2003-03-28 2003-03-28

Publications (1)

Publication Number Publication Date
ATE411038T1 true ATE411038T1 (de) 2008-10-15

Family

ID=33098257

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04723142T ATE411038T1 (de) 2003-03-28 2004-03-25 S100 protein als aktivator neutrophiler zellen zur verminderung der neutropenie bei der krebsbehandlung

Country Status (6)

Country Link
US (1) US7632802B2 (de)
EP (1) EP1608397B1 (de)
AT (1) ATE411038T1 (de)
CA (1) CA2520515C (de)
DE (1) DE602004017148D1 (de)
WO (1) WO2004084928A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553488B2 (en) * 2002-07-05 2009-06-30 UNIVERSITé LAVAL Antibodies against S100A8 and S100A9 proteins for modulating inflammatory reactions
CA2573596A1 (en) * 2004-07-13 2006-01-19 Universite Laval S100 protein inhibitors for treating leukemia
ES2629086T3 (es) * 2006-10-30 2017-08-07 Genomix Co., Ltd. Sustancia farmacéutica para promover la regeneración funcional de tejido dañado
JP5676253B2 (ja) * 2008-04-30 2015-02-25 株式会社ジェノミックス 生体内機能的細胞の高効率採取法
JP5814549B2 (ja) * 2008-04-30 2015-11-17 株式会社ジェノミックス 損傷組織の機能的再生促進医薬
US8673580B2 (en) * 2008-04-30 2014-03-18 Genomix Co., Ltd. Agent for recruitment of bone-marrow-derived pluripotent stem cell into peripheral circulation
US8173598B2 (en) 2008-08-29 2012-05-08 The Board Of Trustees Of The University Of Illinois Myeloid protein activation of anti-inflammatory and anti-hypoxic pathway
JP5865703B2 (ja) 2009-10-28 2016-02-17 株式会社ジェノミックス 骨髄間葉系および／または多能性幹細胞の血中動員による組織再生促進剤
PT3358011T (pt) 2011-04-26 2020-04-23 Univ Osaka Péptido para induzir a regeneração de um tecido e a sua utilização
US9688733B2 (en) 2012-10-25 2017-06-27 Genomix Co., Ltd. Method for treating spinal cord injury using HMGB1 fragment
ES2660420T3 (es) 2012-10-25 2018-03-22 Genomix Co., Ltd. Método novedoso para tratar infarto cardiaco utilizando fragmento de HMGB1
WO2016134463A1 (en) * 2015-02-25 2016-09-01 UNIVERSITé LAVAL S1009a peptide for treating leukemias
EP3556378B1 (de) 2017-01-27 2025-03-12 StemRIM Inc. Therapeutisches mittel für kardiomyopathie, alten myokardinfarkt und chronisches herzversagen
CN111868231B (zh) 2017-12-01 2024-05-31 斯特姆里姆有限公司 外胚层间充质干细胞及其产生方法
CN111542335A (zh) 2017-12-01 2020-08-14 斯特姆里姆有限公司 炎症性肠病的治疗药
US20210024594A1 (en) 2018-02-08 2021-01-28 StemRIM Inc. Therapeutic Agent for Psoriasis
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8318754D0 (en) 1983-07-11 1983-08-10 Fagerhol M K F Human proteins anti-sera test kits
FR2587707B1 (fr) 1985-09-23 1988-01-08 Compiegne Universite Technolog Glycopeptide et toute composition le contenant, leur procede de preparation et leurs applications anticoagulantes
ES2052602T3 (es) 1986-10-03 1994-07-16 Ciba Geigy Ag Nuevos peptidos afines a las linfocinas.
US5714585A (en) 1987-10-26 1998-02-03 Sterling Winthrop, Inc. Antibodies that are immunoreactive with interleukin-7
ATE228164T1 (de) 1990-09-05 2002-12-15 Heart Res Inst Ltd Chemotaktische faktoren
EP0573904B1 (de) 1992-06-08 2001-09-26 Takeda Chemical Industries, Ltd. Therapeutisches Agens für Neutropenie
AU5420796A (en) 1996-03-11 1997-10-01 Human Genome Sciences, Inc. Chemotactic cytokine ii
US5849528A (en) 1997-08-21 1998-12-15 Incyte Pharmaceuticals, Inc.. Polynucleotides encoding a human S100 protein
DE19811047C1 (de) 1998-03-13 1999-04-15 Fraunhofer Ges Forschung Metallhaltige Ribonukleotidpolypeptide
US6117989A (en) 1998-03-26 2000-09-12 Incyte Pharmaceuticals, Inc. Human calcium-binding proteins
AU765719B2 (en) 1998-10-06 2003-09-25 Trustees Of Columbia University In The City Of New York, The Extracellular novel rage binding protein (EN-RAGE) and uses thereof
EP1066834A3 (de) 1999-07-08 2004-06-02 Thomas Dr. Stief Pharmazeutische Zusammensetzungen enthaltend ein phagozytenmodulierendes Agens
DE10121254A1 (de) * 2001-04-30 2002-11-07 Switch Biotech Ag MRP8/MRP14 Heterodimers oder seiner Einzelkomponenten alleine oder in Kombination zur Behandlung und/oder Prävention von Hauterkrankungen, Wunden und/oder Wundheilungsstörungen, die durch eine verringerte Menge an MRP8/MRP14 Heterodimeren gekennzeichnet sind
US7553488B2 (en) 2002-07-05 2009-06-30 UNIVERSITé LAVAL Antibodies against S100A8 and S100A9 proteins for modulating inflammatory reactions
CA2573596A1 (en) 2004-07-13 2006-01-19 Universite Laval S100 protein inhibitors for treating leukemia

Also Published As

Publication number Publication date
WO2004084928A1 (en) 2004-10-07
CA2520515C (en) 2012-08-28
US7632802B2 (en) 2009-12-15
EP1608397B1 (de) 2008-10-15
EP1608397A1 (de) 2005-12-28
DE602004017148D1 (de) 2008-11-27
US20060281674A1 (en) 2006-12-14
CA2520515A1 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
ATE411038T1 (de) S100 protein als aktivator neutrophiler zellen zur verminderung der neutropenie bei der krebsbehandlung
Alvarez et al. Regulatory T cell phenotype and anti-osteoclastogenic function in experimental periodontitis
van Putten et al. Macrophage phenotypes in the collagen-induced foreign body reaction in rats
ATE540129T1 (de) Target zur therapie kognitiver behinderungen
ATE381336T1 (de) Verwendung von a2a adenosin rezeptor agonisten und anti-pathogene mittel enthaltenden kombinationen zur behandlung von entzündungskrankheiten
ATE382053T1 (de) System zur antikörperexpression und- synthese
IS8432A (is) Mótefni sem bindast viðtaka hvítfrumuboða-4
WO2003066072A3 (en) Cell therapy using immunoregulatory t-cells
van Leuven et al. Mycophenolate mofetil attenuates plaque inflammation in patients with symptomatic carotid artery stenosis
Sonouchi et al. Chemokine gene expression in the murine renal cell carcinoma, RENCA, following treatment in vivo with interferon-alpha and interleukin-2
ATE424842T1 (de) Proteine der bcl-2-familie und fragmente davon, und ihre verwendung bei krebspatienten
ATE540973T1 (de) Zusammensetzungen und verfahren zur verwendung von mgd-cdf zur krankheitsbehandlung
DE602005019064D1 (de) Verfahren zur herstellung gefriergetrockneter blutplättchen, gefriergetrocknete blutplättchen enthaltende zusammensetzungen und verwendungsverfahren
NO20045521L (no) Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
JP2009137992A5 (de)
WO2004073657A3 (en) Methods of diagnosis of cancer and other diseases, composition and methods of screening for modulators of cancer and other diseases
EA200600424A1 (ru) Применение полипептидов семейства купредоксинов при лечении рака
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
Mocellin et al. Use of quantitative real-time PCR to determine immune cell density and cytokine gene profile in the tumor microenvironment
EA200600936A1 (ru) Способы регуляции фактора некроза опухоли альфа
CN105506155A (zh) 检测长链非编码rna loc284454表达量的试剂的应用
ATE469659T1 (de) Stibogluconate-natrium und il-2 zur krebsbehandlung
Arai et al. A solid tumor of donor cell-origin after allogeneic peripheral blood stem cell transplantation
DE60130775D1 (de) Stimulierung der neutrophilfunktion zur behandlung von entzündlichen darmerkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties